

CURRICULUM VITAE



Professor EMAD M EL-OMAR

B.Sc. (Hons.); MB, Ch.B.; M.D. (Hons); FRCP (Edin)

NAME: Emad Munir El-Omar

DATE OF BIRTH: 23.07.1962

ADDRESS: Department of Medicine & Therapeutics
University Of Aberdeen
Room 6.20, Institute of Medical Sciences, Foresterhill, Aberdeen
AB25 2ZD
Tel: ++44-(0) 1224-553021 (direct)
Fax: ++44-(0) 1224-554761
E-mail: e.el-omar@abdn.ac.uk

NATIONALITY: British.

MARITAL STATUS: Married (5 children, 3 boys & 2 girls).

CCST: General Medicine & Gastroenterology, 11.11.1997

SCHOOL EDUCATION: Davies College, Hove, England.
Four passes at "A" level in Biology, Chemistry,
Physics and Pure Maths. Awarded the Davies
College Biology Prize 1981.

UNIVERSITY EDUCATION: University of Glasgow, 1981-1988.

DEGREES & DIPLOMAS: B.Sc. (Hons) in Pathology, (1986).
M.B., Ch.B., (1988).
M.R.C.P. (UK), (1991).
M.D. Awarded **With Honours and Belahouston
Medal** July, 1995. **Title:** The Effect of *Helicobacter
pylori* Infection on Gastric Acid Secretion in Man.
FRCP (Edinburgh), 2002

POSTGRADUATE PRIZES & FELLOWSHIPS:

- *The **Fitzgerald-Peel Research Fellowship Award and Prize** 1992, Scottish Society of Physicians.
- *Best Research prize at the **European *Helicobacter pylori* Workshop**, Brussels, Belgium 1993.
- *The **Belahouston Medal** for the most distinguished MD thesis submitted to University of Glasgow in the session 1994-1995.
- *The **Astra prize**, Caledonian Society of Gastroenterology, 1995.
- *Two year fellowship (1997-1999) awarded by the **European *Helicobacter pylori* Study Group**, through the **Digestive Disorders Foundation**, to study the bacterial and host genetic factors that determine the clinical outcome to *H. pylori* infection and its relationship to gastric cancer.
- ***Young Investigator Award**, American Association for Cancer Research Meeting, San Francisco, USA, 2000.
- ***Scientific Excellence Award 2000**, National Cancer Institute, Bethesda, Maryland, USA

Membership of Professional Societies and Organisations

Member of the Association of Physicians of Great Britain and Ireland
Fellow of the Royal College of Physicians of Edinburgh
Member of the American Gastroenterological Association
Member of the British Society of Gastroenterology
Member of the Prout Club
Member of the European Gastro Club
Member of the American Association for Cancer Research
Member of the Scottish Society of Gastroenterology

Editorial Duties

I am associate editor of the journal GUT. I also sit on the international editorial boards of Alimentary Pharmacology & Therapeutics, Helicobacter and Digestive and Liver Diseases

POST-REGISTRATION APPOINTMENTS:

August 1989- July 1991

The Western Rotational Training Programme, Western Infirmary, Glasgow, culminating in Membership of the Royal College of Physicians (MRCP, UK).

August 1991- September 1993

Full-time Research Fellow in Gastroenterology at the University Department of Medicine and Therapeutics, Western Infirmary, Glasgow.

September 1993- July 1995:

Lecturer in Medicine and Gastroenterology, Honorary Career Registrar, University of Glasgow and Greater Glasgow Health Board.

July 1995- August 1997

Lecturer in Medicine, Honorary Senior Registrar, University of Glasgow and Greater Glasgow Health Board.

August 1997- November 1998

Visiting Scholar, Department of Medicine, Vanderbilt University Medical Centre, Nashville, Tennessee, USA.

November 1998- July 2000

Visiting Scientist, National Cancer Institute/ National Institutes of Health, Bethesda, Maryland, under the leadership of Dr Joseph Fraumeni, Head of the Division of Cancer Genetics and Epidemiology. During the year August 1999 and June 2000, I was appointed as part-time Professor of Gastroenterology at Aberdeen University, in anticipation of my arrival full time in July 2000.

July 2000- Current

I was appointed as **Professor of Gastroenterology** and **Honorary Consultant Physician** at the University of Aberdeen and Grampian University Hospitals, Aberdeen, Scotland. I took up this position full time on **July 1st, 2000**.

CLINICAL EXPERIENCE:

I am a fully qualified Internist and Gastroenterologist having been awarded the UK's Certificate of Completion of Specialist Training (CCST) in 1997.

RESEARCH INTERESTS

- Role of gene-environment interactions in pathogenesis of GI disease.
- Pathogenesis of *Helicobacter pylori* infection and its role in peptic ulcer disease, dyspepsia and gastric cancer
- Role of host genetic factors in the pathogenesis of upper GI malignancy
- Role of chronic inflammation in GI malignancy
- Role of gut microbiota in the pathogenesis of colorectal cancer and inflammatory bowel disease

PUBLICATIONS:

PAPERS

MCCOLL KEL, THOMPSON GG, **EL-OMAR E**, MOORE MR, GOLDBERG A.
Porphyrin metabolism and haem biosynthesis in Gilbert's syndrome. **Gut**, 1987; 28: No.2: 125-130.

McCOLL KEL, THOMPSON GG, **EL-OMAR E**, MOORE MR, PARK BK, BRODIE MJ.
Effect of rifampicin on haem and bilirubin metabolism in man. **British Journal of Clinical Pharmacology**, 1987; 23: 553-559.

ANTHONY RS, **EL-OMAR E**, LAPPIN D, MacSWEEN RNM, WHALEY K.
Regulation of hepatic synthesis of C3 and C4 during the acute phase response in the rat. **European Journal of Immunology**, 1989; 19: 1405-1412.

McCOLL KEL, EL-NUJUMI AM, CHITTAJALLU RS, DAHILL S, DORRIAN CA, **EL-OMAR E**, PENMAN I, FITZSIMMONS EJ, DRAIN J, GRAHAM H, ARDILL JES, BESSENT R.
A study of the pathogenesis of *Helicobacter pylori* negative chronic duodenal ulceration. **Gut**, 1993; 34: 762-768.

EL-OMAR E, PENMAN I, DORRIAN CA, ARDILL JES, McCOLL KEL.
Eradication of *Helicobacter pylori* infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer. **Gut**, 1993; 34: 1060-1065.

PENMAN I, **EL-OMAR E**, MCGREGOR JR, HILLAN KJ, O'DWYER PJ, McCOLL KEL.
Omeprazole inhibits azoxymethane-induced colorectal carcinogenesis in rats. **Gut**, 1993; 34: 1559-1565.

EL-OMAR E, PENMAN I, SPENCE E, ARDILL JES, McCOLL KEL.
The GRP test : a new clinical test of acid secretion - Reproducibility data.
European Journal of Gastroenterology and Hepatology, 1994; 6: 417-421.

EL-OMAR E, PENMAN I, CRUIKSHANK G, DOVER S, BANERJEE S, WILLIAMS C, McCOLL KEL.
Low prevalence of *Helicobacter pylori* in inflammatory bowel disease: association with sulphasalazine.
Gut, 1994; 35: 1385-1388.

EL-OMAR E, McCOLL KEL.
Helicobacter pylori eradication, duodenal ulcer healing, and gastric secretory state.
Gut, 1994; 35: 571.

McCOLL KEL, **EL-OMAR E**, BANERJEE S.
Duodenal ulcer healing drugs. **Lancet**, 1994; 343:915.

PENMAN ID, **EL-OMAR E**, ARDILL JES, McGREGOR JR, GALLOWAY DJ, O'DWYER PJ, McCOLL KEL.

Plasma gastrin concentrations are normal in patients with colorectal neoplasia and unaltered following tumour resection.

Gastroenterology, 1994; 106: 1263-1270.

EL-OMAR E, PENMAN I, ARDILL JES, McCOLL KEL.

A substantial proportion of NUD patients have the same abnormality of acid secretion as DU patients.

Gut, 1995; 36: 534-538.

EL-OMAR E, PENMAN I, ARDILL JES, CHITTAJALLU RS, HOWIE C, McCOLL KEL.

Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease.

Gastroenterology, 1995; 109: 681-691.

BANERJEE S, **EL-OMAR E**, MOWAT A, ARDILL JES, PARK RHR, WATSON W, BEATTIE AD, MCCOLL KEL.

Sucralfate suppresses *H pylori* infection & reduces gastric acid secretion by 50% in DU patients.

Gastroenterology, 1996, 110: 717-724.

EL-OMAR E, BANERJEE S, WIRZ A, PENMAN I, ARDILL JES, McCOLL KEL.

Marked rebound acid hypersecretion following treatment with ranitidine.

American Journal of Gastroenterology, 1996; Vol.91, No.2: 355-359.

McCOLL KEL, **EL-OMAR E**.

Helicobacter pylori infection and disturbance of gastric function associated with duodenal ulcer and gastric cancer.

Scandinavian Journal of Gastroenterology, 1996; 31 suppl. 215: 32-37.

EL-OMAR E, GILLEN D, McCOLL KEL

Gastrin-releasing peptide, *Helicobacter pylori*, and duodenal ulcer: another epiphenomenon? (Letter).

Gastroenterology, 1996; 110: 1325-1326.

EL-OMAR E, BANERJEE S, WIRZ A, McCOLL KEL.

The Glasgow Dyspepsia Severity Score - A tool for the global measurement of dyspepsia.

European Journal of Gastroenterology and Hepatology, 1996, 8 (10): 967-971.

EL-OMAR E, OIEN K, EL-NUJUMI A, GILLEN D, WIRZ A, DAHILL S, WILLIAMS C, ARDILL JES, McCOLL KEL.

Helicobacter pylori infection and chronic gastric acid hyposecretion. **Gastroenterology**, 1997; 113(1): 15-24.

McCOLL KEL, EL-NUJUMI A, MURRAY L, **EL-OMAR E**, GILLEN D, DICKSON A, KELMAN A, HILDITCH TE

The *Helicobacter pylori* breath test : a surrogate marker for peptic ulcer disease in dyspeptic patients. **Gut**, 1997; 40(3): 302-306.

GILLEN D, **EL-OMAR E**, WIRZ A, ARDILL JE, McCOLL KE
The acid response to gastrin distinguishes duodenal ulcer patients from *Helicobacter pylori*-infected healthy subjects. **Gastroenterology**, 1998; 114(1): 50-57.

McCOLL KEL, EL-NUJUMI A, MURRAY LS, **EL-OMAR EM**, DICKSON A, KELMAN AW, HILDITCH TE.
Assessment of symptomatic response as predictor of *Helicobacter pylori* status following eradication therapy in patients with ulcer. **Gut**, 1998; 42(5): 618-622.

MCCOLL KEL, MURRAY L, **EL-OMAR E**, DICKSON A, EL-NUJUMI A, WIRZ A,KNILL-JONES R.
The UK MRC trial of eradication of *H. pylori* infection in non ulcer dyspepsia. **New England Journal of Medicine**, 1998; Vol. 339: 1869-1874.

SMITH A, GILLEN D, **EL-OMAR E**, COCHRAN K, McCOLL KEL.
Rebound dyspepsia following ranitidine treatment. **American Journal of Gastroenterology**, 1999; 94(5):1209-1213.

McCOLL KEL, MURRAY L, **EL-OMAR E**.
Helicobacter pylori and nonulcer dyspepsia. **New England Journal of Medicine** 1999; 340(19):1509; discussion 1509-11.

MITCHELL L. SCHUBERT, KENNETH E. L. McCOLL, LILIAN S. MURRAY, and **EMAD M. EL-OMAR**.
H. pylori and nonulcer dyspepsia: not guilty as charged. **Gastroenterology** 1999 117: 270-272.

McCOLL KEL, DICKSON A, EL-NUJUMI A, **EL-OMAR E**, KELMAN A.
Symptomatic benefit 1-3 years post *H. pylori* eradication in ulcer patients: impact of gastroesophageal reflux disease. **American Journal of Gastroenterology** 2000; 95(1): 101-5.

EL-OMAR EM, OIEN K, MURRAY LS, EL-NUJUMI A, WIRZ A, GILLEN D, WILLIAMS C, FULLARTON G, McCOLL KEL.
Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of *H. pylori*. **Gastroenterology**, 2000; 118: 22-30.

EL-OMAR EM, CARRINGTON M, CHOW W-H, McCOLL KE, BREAM J, YOUNG HA, HERRERA J, LISSOWSKA J, YUAN C-C, ROTHMAN N, LANYON G, MARTIN M, FRAUMENI JF Jr, RABKIN CS.
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. **Nature**, 2000; 404(6776): 398-402.

MCCOLL KE, **EL-OMAR E**, GILLEN D.
Helicobacter pylori gastritis and gastric physiology. **Gastroenterol Clin North Am.** 2000 Sep;29(3):687-703, viii.

El-Omar E.
The importance of interleukin-1 β in *Helicobacter pylori*-associated disease. Leading article, **GUT**, 2001; 48: 743-747.

EL-OMAR EM, CHOW WH, RABKIN CS

Gastric Cancer and *H. pylori*: Host Genetics Open the Way. **Gastroenterology**, 2001; 121(4):1002-1005.

FURUTA T, **EL-OMAR EM**, XIAO F, SHIRAI N, TAKASHIMA M, SUGIMURRA H.
Effect of genetic polymorphism in Interleukin-1 β on gastritis, gastric juice pH, and recurrence of peptic ulcer disease in Japanese subjects. **Gastroenterology**, 2002; 123(1): 92-105.

Takata T, **EL-OMAR EM**, Camorlinga M, Thompson SA, Minohara Y, Ernst PB, Blaser MJ.
Helicobacter pylori does not require Lewis X or Lewis Y expression to colonize C3H/HeJ mice. **Infection & Immunity**, 2002; 70: 3073-3079.

McCull KE, **El-Omar E**
E-cadherin germline mutations and risk of gastric cancer.
Gastroenterology, 2002; 123(4): 1406.

El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert JJ, Blot WJ, Fraumeni Jr JF, Chow WH.
Increased risk of non-cardia gastric cancer associated with pro-inflammatory cytokine gene polymorphisms. **Gastroenterology**, 2003; 124: 1193-1201.

Furutra T, Shirai N, Xiao F, **El-Omar EM**, Rabkin CS, Sugimura H, Ishizaki T, Ohashi K.
Polymorphism of interleukin-1 β affects the eradication rates of *Helicobacter pylori* by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. **Clinical Gastroenterology & Hepatology**, 2004; 2(1):22-30.

Toshi Nada, Takafumi Ando, Kazuo Nobata, Tomoyuki Tsuzuki, Kenji Ina, Yoshitsugu Inuma, Satoshi Ichiyama, Michio Ohta, **Emad El-Omar**, Kazuo Kusugami, Hidemi Got. Sensitivity of *Helicobacter pylori* to Amoxicillin, Metronidazole and Clarithromycin after eradication therapy. **Alimentary Pharmacology & Therapeutics**, 2004; 20 Suppl 1:39-47.

de Sanjose S, Dickie A, Alvaro T, Romagosa V, Villanueva MG, Domingo-Domenech E, de Sevilla AF, **El-Omar EM**. *Helicobacter pylori* and malignant lymphoma in Spain. **Cancer Epidemiology Biomarkers and Prevention**, 2004; 13(6):944-8.

Garza-González E, Bosques-Padilla FJ, **El-Omar E**, Hold G, Tijerina-Menchaca R, Maldonado-Garza HJ, Pérez-Pérez GI. Role of the polymorphic *IL-1B*, *IL-1RN* AND *TNF-A* genes in distal gastric cancer in Mexico. **International Journal of Cancer**, paper in press.
Garza-Gonzalez E, Hold G, Perez-Perez GI, Bosques-Padilla FJ, Tijerina-Menchaca R, Maldonado-Garza HJ, **El-Omar E**. Role of polymorphism of certain cytokines in gastric cancer in Mexico. Preliminary results. **Rev Gastroenterol Mex**. 2003 Apr-Jun;68(2):107-12

Furutra T, Shirai N, Xiao F, **El-Omar EM**, Rabkin CS, Sugimura H, Ishizaki T, Ohashi K.
Polymorphism of interleukin-1 β affects the eradication rates of *Helicobacter pylori* by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. **Clinical Gastroenterology & Hepatology**, 2004; 2(1):22-30.

Toshi Nada, Takafumi Ando, Kazuo Nobata, Tomoyuki Tsuzuki, Kenji Ina, Yoshitsugu Inuma, Satoshi Ichiyama, Michio Ohta, **Emad El-Omar**, Kazuo Kusugami, Hidemi Got. Sensitivity of *Helicobacter pylori* to Amoxicillin, Metronidazole and Clarithromycin after eradication therapy. **Alimentary Pharmacology & Therapeutics**, 2004; 20 Suppl 1:39-47.

de Sanjose S, Dickie A, Alvaro T, Romagosa V, Villanueva MG, Domingo-Domenech E, de Sevilla AF, **El-Omar EM**. *Helicobacter pylori* and malignant lymphoma in Spain. **Cancer Epidemiology Biomarkers and Prevention**, 2004; 13(6):944-8.

Macarthur M, Hold GL, **El-Omar EM**. Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. **Am J Physiol Gastrointest Liver Physiol**. 2004 Apr;286(4):G515-20.

Garza-González E, Bosques-Padilla FJ, **El-Omar E**, Hold G, Tijerina-Menchaca R, Maldonado-Garza HJ, Pérez-Pérez GI. Role of the polymorphic *IL-1B*, *IL-1RN* AND *TNF-A* genes in distal gastric cancer in Mexico. **International Journal of Cancer**, 2005 Mar 20;114(2):237-41

Hope ME, Hold GL, Kain R, **El-Omar EM**. Sporadic colorectal cancer--role of the commensal microbiota. **FEMS Microbiol Lett**. 2005 Mar 1;244(1):1-7.

Macarthur M, Sharp L, Hold GL, Little J, **El Omar EM**. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. **Cancer Epidemiol Biomarkers Prev** 2005;14:1613-1618.

Minami M, Ando T, Ina K, Kusugami K, **El-Omar EM**, Goto H. Long term follow-up following eradication of *Helicobacter pylori* with omeprazole, clarithromycin, and tinidazole (OCT regimen) in a Japanese population. **Helicobacter**, 2005 Oct;10(5):379-84.

Ando T, **El-Omar EM**, Goto Y, Nobata K, Watanabe O, Maeda O, Ishiguro K, Minami M, Hamajima N, Goto H. *IL-1* beta pro-inflammatory genotypes protect against gastro-oesophageal reflux disease through induction of corpus atrophy. **GUT**, 2006 Feb;55(2):158-64. Epub 2005 Aug 24

Goto Y, Ando T, Yamamoto K, Tamakoshi A, **El-Omar E**, Goto H, Hamajima N. Association between serum pepsinogens and polymorphism of PTPN11 encoding SHP-2 among *Helicobacter pylori* seropositive Japanese. **Int J Cancer** 2006 Jan 1;118(1):203-8

Smith MG, Hold GL, Tahara E, **El-Omar EM**. Cellular and molecular aspects of gastric cancer. **World Journal of Gastroenterology**, paper in press.

El-Omar EM. Mechanisms of increased acid secretion after eradication of *Helicobacter pylori* infection. **GUT**, 2006 Feb;55(2):144-6

El-Omar EM. What is the optimal duration of Rabeprazole triple therapy for the eradication of *Helicobacter pylori*. **Nature Clinical Practice Gastroenterology & Hepatology**, in press.

McLean M, Hold GL, **El-Omar EM**. The role of chronic inflammation in sporadic colorectal cancer. **GUT**, Leading article in press.

El-Omar EM. Pitfalls in studying polymorphisms: have they advanced our understanding of disease? **GUT**, Leading article, in press.

Hold GL, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA, Vaughan TL, McColl KEL, Lissowska J, Zatonski W, Schoenberg JB, Blot WJ, Mowat NAG, Fraumeni JF Jr., **El-Omar EM**. A functional polymorphism of Toll-like receptor 4 gene increases risk of gastric cancer and its precursors. **Gastroenterology**, Paper in press.

Hisada M, Gold BD, Kim N, **El-Omar EM**, Cranston B. Prevalence, incidence and clearance of *Helicobacter pylori* infection in Jamaican children. **Emerging Infectious Diseases**, paper in press.

Tseng FC, Brown EE, Maiese E, Yeager M, Welch R, Gold BD, Cranston B, Hanchard B, **El-Omar EM**, Hisada M. Polymorphisms in Cytokine Genes and Risk of *Helicobacter pylori* Infection among Jamaican Children. **Cancer Epidemiology Biomarkers and Prevention**, Paper in press.

Hou L, **El-Omar EM**, Chen J, Grillo P, Rabkin C, Baccarelli A, Yeager M, Chanock SJ, Zatonski W, Sobin LH, Lissowska J, Fraumeni JF Jr, Chow WH. Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. **Carcinogenesis**, Paper in press.

Baccarelli A, Hou L, Chen J, Lissowska J, **El-Omar EM**, Grillo P, Giacomini SM, Yaeger M, Bernig T, Zatonski W, Fraumeni JF Jr., Chanock SJ, Chow WH. Mannose-Binding Lectin-2 genetic variation and stomach cancer risk. **Int J Cancer**, Paper in press.

REVIEW ARTICLES

McCOLL KEL, **EL-OMAR E**.
Why *H pylori* eradication holds the key in DU disease.
Prescriber, 1994; Vol. 5: No. 6: 20-26.

McCOLL KEL, **EL-OMAR E**.
Gastrin Releasing Peptide and its value in assessing gastric secretory function. **Alimentary Pharmacology & Therapeutics**, 1995; 9: 341-347.

MCCOLL KEL, **EL-OMAR E**, GILLEN D
The role of *H. pylori* infection in the pathophysiology of duodenal ulcer disease.
J Physiol Pharmacol, 1997; 48(3): 287-295.

MCCOLL KEL, **EL-OMAR E**, GILLEN D, BANERJEE S
The role of *Helicobacter pylori* infection in the pathogenesis of duodenal ulcer disease and gastric cancer. **Seminars in Gastrointestinal Disease**, 1997; 8(3): 142-155.

McCOLL KE, **EL-OMAR EM**, GILLEN D
Alterations in gastric physiology in *Helicobacter pylori* infection: causes of different diseases or all epiphenomena? **Ital J Gastroenterol Hepatol** 1997 Oct; 29(5):459-64.

McCOLL KE, **EL-OMAR E**, GILLEN D
Interactions between *H. pylori* infection, gastric acid secretion and anti-secretory therapy.
Br Med Bull 1998;54(1):121-38.

MCCOLL KE, GILLEN D, **EL-OMAR E**.
The role of gastrin in ulcer pathogenesis. **Baillieres Best Pract Res Clin Gastroenterol**. 2000 Feb; 14(1): 13-26.

EL-OMAR E, MALFERTHEINER P
The year in *Helicobacter pylori* 2001: *H. pylori* and gastric cancer. **Current Opinion in Gastroenterology**, 2001; 17 (suppl 1): S24-S27.

McColl KE, **El-Omar E**

How does *H. pylori* infection cause gastric cancer?

Keio J Med. 2002 Dec; 51 Suppl 2:53-6.

TROOST E, HOLD GL, SMITH MG, CHOW WH, RABKIN CS, MCCOLL KE, **EL-OMAR EM**. The role of interleukin-1beta and other potential genetic markers as indicators of gastric cancer risk. Can J Gastroenterol. 2003 Jun; 17Suppl B:8B-12B.

McLeman L, McKinlay A, **El-Omar EM**. Management of dyspeptic patients in primary care. The Practitioner, paper in press.

El-Omar EM. Role of host genes in sporadic gastric cancer. . **Baillieres Best Pract Res Clin Gastroenterol**, paper in press.

El-Omar EM. *Helicobacter pylori* and gastric cancer. **Baillieres Best Pract Res Clin Gastroenterol**, paper in press.

BOOKS

Rapid Reference to Dyspepsia

Emad M El-Omar and Richard Peek Jr. Mosby, 2003.

CHAPTERS IN BOOKS

McCOLL KEL, **EL-OMAR E**

Effect of *H pylori* infection on gastrin and gastric acid secretion.

In Hunt RH and Tytgat GNJ (eds): *Helicobacter pylori*: Basic Mechanisms to Clinical Cure. Kluwer Academic Publishers. 1994; 245-256.

McCOLL KEL, GILLEN D, **EL-OMAR E**, OIEN K, DAHILL S.

Helicobacter pylori gastritis and gastric acid secretory function – an integrated approach. In: Hunt RH, Tytgat GNJ eds. *Helicobacter pylori*. Basic Mechanisms to Clinical Cure 1996. Kluwer Academic Publishers, Boston, 1996: 122-31.

McCOLL KEL, **EL-OMAR E**

Mechanisms involved in the development of hypochlorhydria and pangastritis in *Helicobacter pylori* infection. In: Hunt RH, Tytgat GNJ eds. *Helicobacter pylori*. Basic Mechanisms to Clinical Cure 2000. Kluwer Academic Publishers, Dordrecht: NL, 2000: 373-384.

EL-OMAR EM.

Analysis of single nucleotide polymorphisms in the interleukin-1B gene using 5' nuclease assays. In O'Neill L.A. J and Bowie A. (eds): *Methods in Molecular Medicine*, vol.60: Interleukin Protocols. Humana Press Inc., Totowa NJ.

EL-OMAR EM.

Gastric Cancer in the Elderly. In: Alberto Pilotto; Peter Malfertheiner; Peter Holt (eds): *Interdisciplinary Topics in Gerontology: Aging and the Gastrointestinal Tract*. Karger AG Press. 2003: 145-156.

ESTHER TROOST, GEORGINA HOLD, MALCOLM SMITH, WONG-HO CHOW,
CHARLES C RABKIN, KENNETH EL McCOLL, and **EMAD M EL-OMAR**

The role of IL-1beta and other potential genetic markers as indicators of gastric cancer risk. In:
Hunt RH, Tytgat GNJ eds. *Helicobacter pylori*. Basic Mechanisms to Clinical Cure 2002. Kluwer
Academic Publishers, 2003; 215-223.

EL-OMAR EM AND RABKIN CS

Host susceptibility to microbial infection and cancer. In: Persing D, Tenover F, Versalovic J,
Tang Y, Unger B, Relman D, and White T, (eds): *Molecular Microbiology, Diagnostic Principles
and Practice*. 2004: 671-678.

EL-OMAR EM. The role of interleukin 1 beta in *Helicobacter pylori* associated disease.
In Kurhaus Symposia Series, 2004.

Alastair McKinlay and **Emad M El-Omar**. Adenocarcinoma (gastric cancer and
miscellaneous malignancy). In Weinstein, Hawkey and Bosch (Eds): *Clinical
Gastroenterology and Hepatology*. 2005, Elsevier Mosby. ISBN 0-323-02751-2